RE:RE:RE:ValuationLithLover, Nailbiter1 and brad129..good post...
In the Richmond Club video Jan 23, 2019...
https://Plus.google.com/+WeedWarrior/posts/PH11vherjts Genenews said (QUOTE) We are at that tipping point were everything is falling into place...we believe we will do CAD30 million in 2019, that is way above our breaking point (END of Quote).
-Way above our breaking point...mean a big part of that 30 million will be profit.
-When the word ''Profit'' come up into the Revenue Report of a company , you can bet your shirt that the valuation will go up much faster.
-Having said that I will take your 5 to 20 time with great pleasure.
PS: When we compare to EXAS:US($82USD), we always have to remember that EXAS:US has revenue but no profit.
-Genenews on the other hand at the end of 2019 could have revenue and profit.
brad129 wrote: Nailbiter1 wrote: AMEN to that bro.
LithLover wrote: I’ve been researching a lot of bio tech and pharmacy stock valuations. Long story short is that valuations range from 5 times revenues to upwards of 20. If Tripp can hit 30 million taking the low end of 5 times is 150 million putting us a $1 a share. High end $5 a share. I’ll hang onto my shares for a 10 bagger from here for 9 months. Duh
Last time I looked it up Exas was 26 times revenue now keep in mind that’s 26 times actual revenue. If James is correct and not exaggerating 30 million that valuation will be seen as we show progress.